Press Releases

    Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma  
    Kazia Announces Upcoming DIPG Data Presentations at ISPNO And Publication in European Journal of Cancer  
    Kazia Reports Successful Stage 1 Completion Of The Evt801 Phase 1 Clinical Trial In Advanced Cancer Patients  
    Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases  
    Kazia announces presentation of new data at AACR Annual Meeting  
    Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint  
    Kazia Continues Board Renewal With Two New Appointments  
    Resignation of Chief Financial Officer; Appointment of Principal Accounting Officer and Principal Financial Officer  
    Kazia Therapeutics Announces $2 Million Registered Direct Offering  
    Kazia AGM - Chairman's Address  
    Kazia 2023 Annual General Meeting R&D and Clinical Overview  
    Kazia AGM Meeting results  
    Kazia Announces Non-binding Letter of Intent for the Proposed Granting of Rights to Develop and Commercialize Paxalisib Outside of Oncology  
    Kazia Provides Overview Of Paxalisib Related Presentations from the Society Of Neuro-oncology 2023 Annual Meeting